UKALL60+ offered four treatment “pathways”: pathway A for BCR::ABL1+ ALL and pathways B, C, and D offering three choices of intensity for BCR::ABL1 negative ALL (Intensive, Intensive‐plus and Non‐Intensive, respectively), to be selected by investigator and patients. Here, ABL1 is linked to acute lymphoblastic leukemia.